Department of Cardiovascular Medicine (J.M., S. Takada, T.F., H.N., N.K., S.M., W.M., I.N., A.F., T.Y., S.K.), Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Department of Cancer Pathology (S. Tanaka), Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Circ Heart Fail. 2021 Jan;14(1):e005890. doi: 10.1161/CIRCHEARTFAILURE.119.005890. Epub 2020 Dec 28.
We recently reported that treatment with rhBDNF (recombinant human brain-derived neurotrophic factor) improved the reduced exercise capacity of mice with heart failure (HF) after myocardial infarction (MI). Since BDNF is reported to enhance fatty acid oxidation, we herein conducted an in vivo investigation to determine whether the improvement in exercise capacity is due to the enhancement of the fatty acid oxidation of skeletal muscle via the AMPKα-PGC1α (adenosine monophosphate-activated protein kinase-ɑ-proliferator-activated receptor-r coactivator-1ɑ) axis.
MI and sham operations were conducted in C57BL/6J mice. Two weeks postsurgery, we randomly divided the MI mice into groups treated with rhBDNF or vehicle for 2 weeks. AMPKα-PGC1α signaling and mitochondrial content in the skeletal muscle of the mice were evaluated by Western blotting and transmission electron microscopy. Fatty acid β-oxidation was examined by high-resolution respirometry using permeabilized muscle fiber. BDNF-knockout mice were treated with 5-aminoimidazole-4-carboxamide-1-beta-d-riboruranoside, an activator of AMPK.
The rhBDNF treatment significantly increased the expressions of phosphorylated AMPKα and PGC1α protein and the intermyofibrillar mitochondrial density in the MI mice. The lowered skeletal muscle mitochondrial fatty acid oxidation was significantly improved in the rhBDNF-treated MI mice. The reduced exercise capacity and mitochondrial dysfunction of the BDNF-knockout mice were improved by 5-aminoimidazole-4-carboxamide-1-beta-d-riboruranoside.
Beneficial effects of BDNF on the exercise capacity of mice with HF are mediated through an enhancement of fatty acid oxidation via the activation of AMPKα-PGC1α in skeletal muscle. BDNF may become a therapeutic option to improve exercise capacity as an alternative or adjunct to exercise training.
我们最近报道称,rhBDNF(重组人脑源性神经营养因子)治疗可改善心肌梗死后心力衰竭(HF)小鼠的运动能力下降。由于 BDNF 据报道可增强脂肪酸氧化,因此我们在此进行了一项体内研究,以确定运动能力的改善是否是由于通过 AMPKα-PGC1α(腺苷单磷酸激活蛋白激酶-α-过氧化物酶体增殖物激活受体-r 共激活因子-1α)轴增强骨骼肌的脂肪酸氧化所致。
在 C57BL/6J 小鼠中进行 MI 和假手术。手术后 2 周,我们将 MI 小鼠随机分为 rhBDNF 治疗组或载体治疗组,治疗 2 周。通过 Western blot 和透射电镜评估小鼠骨骼肌中的 AMPKα-PGC1α 信号和线粒体含量。通过使用透化肌纤维的高分辨率呼吸测定法检查脂肪酸 β-氧化。用 5-氨基咪唑-4-甲酰胺-1-β-D-核糖呋喃苷(一种 AMPK 激活剂)处理 BDNF 敲除小鼠。
rhBDNF 治疗可显著增加 MI 小鼠磷酸化 AMPKα 和 PGC1α 蛋白的表达以及肌间纤维线粒体密度。rhBDNF 治疗可显著改善 MI 小鼠骨骼肌线粒体脂肪酸氧化降低的情况。5-氨基咪唑-4-甲酰胺-1-β-D-核糖呋喃苷可改善 BDNF 敲除小鼠的运动能力下降和线粒体功能障碍。
BDNF 对 HF 小鼠运动能力的有益影响是通过激活骨骼肌中的 AMPKα-PGC1α 来增强脂肪酸氧化来介导的。BDNF 可能成为一种治疗选择,以改善运动能力,作为运动训练的替代或辅助手段。